BioConsortia, Inc., a leading agricultural technology company that discovers, designs and out licenses advanced microbial products to reduce the ecological impacts of agriculture while ensuring crop productivity, this week unveiled the latest results of SOLVARIX bionematicide field testing during an industry meeting in Campinas, Brazil. The company also shared latest yield findings from Brazilian trials of ALWAYS-N seed treatments and conducted meetings with commercial partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240805806999/en/

In field studies conducted by third-party researchers throughout the USA and Brazil, Solvarix bionematicide was shown to control corn nematodes and improve yields more effectively than leading chemical nematicdes. (Credit: BioConsortia 2024)

In a presentation to the participants at the BioControl and BioStimulant – LATAM meeting, Dr. Debora Wilk, BioConsortia’s Director of Plant Pathology, unveiled the latest results of SOLVARIX bionematicide testing in Brazil. Dr. Wilk shared the strengths of SOLVARIX bionematicide and its strong fit for the Brazilian market. “SOLVARIX, in both USA and Brazil, has demonstrated direct control of important nematode pests and increased corn yields 578 kilograms per hectare (8.6 bushels per acre) on average,” said Dr. Wilk. “The product is highly consistent, delivering increased yields in 91% of all trials, and outperforms leading chemical nematicides in both yield contribution and consistency.”

The Brazilian bionematicide market is growing rapidly, from 160 million Brazilian Reales in 2014 to 1.6 billion Reales in 2021. The growth reflects the emergence of nematodes as a critical yield-destroying pest in Brazilian agriculture and a lack of sufficient chemical products to meet the pest challenge.

“BioConsortia’s microbial seed treatment products are an excellent fit for nematode challenges impacting key crops in Brazil like corn, soybean, sugarcane, cotton and vegetables,” said Marcus Meadows-Smith, the company’s CEO. “Based on a patented strain of spore-forming microbes isolated using our powerful AMS strain discovery system, SOLVARIX is shelf stable for two years and on-seed stable for an additional two years. This eases grower handling and storage of the product and opens a new addressable market among Brazil’s seed companies.”

BioConsortia is pursing registrations and anticipates launching SOLVARIX bionematicide through seed and crop protection partners, initially in Brazil and USA beginning in 2026, with global commercialization to follow.

ABOUT BIOCONSORTIA

BioConsortia, Inc. develops superior microbial products that protect plants, enhance fertility, and increase yields while improving the sustainability of agriculture for our environment. Pioneering the use of directed selection within microbial communities, our patented Advanced Microbial Selection (AMS) process and cutting-edge GenePro genomics and gene-engineering platform enable us to predict, design, and unleash the natural power of microbes.

BioConsortia’s microbial products deliver superior efficacy, higher consistency, and easier grower adoption. The Company’s rich pipeline includes nitrogen fixation microbes to replace or reduce synthetic nitrogen fertilizers; nutrient use efficiency and biostimulants to increase crop yields; bionematicides & biofungicides to protect crops from pests and diseases; and products for post-harvest pathogen control to safeguard food waste in the distribution chain, retail store and home. BioConsortia is producing breakthrough solutions for growers in major agricultural markets with multiple environmental benefits.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240805806999/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.